Bayhill doses patients with multiple sclerosis in phase II trial, raises $15.8M
Science Letter - May. 12, 2006
Bayhill Therapeutics, Inc., has begun dosing patients with BHT-3009, the company's experimental drug candidate, in a phase II company sponsored trial for multiple sclerosis.
The phase II study is a multicenter, double-blind, placebo-controlled evaluation with an MRI endpoint. In a related development, current investors indicated strong support for Bayhill's antigen-specific tolerance platform by raising an additional $15.8 ...